Table 4.

Olanzapine compared to TBZ

Results of Propensity Score Matched Analysis
	Direction of favorable Δ	TBZ Group	Olanzapine Group	P‐value
N		77	77
Primary Outcome Measure
Annual rate of Δ of TMS	−	5.69 ± 11.09	3.20 ± 9.77	0.143
Secondary Outcome Measures
Absolute Δ of TMS	−	5.96 ± 12.06	3.43 ± 9.87	0.156
Percent Δ of TMS	−	20.61 ± 43.40	12.93 ± 31.95	0.213
Annualized percent Δ of TMS	−	19.08 ± 39.75	11.96 ± 30.58	0.215
Annual rate of Δ of total chorea score	−	0.30 ± 4.65	−0.13 ± 4.47	0.563
Annual rate of Δ of TFC	+	−0.84 ± 1.60	−0.73 ± 1.38	0.637
Annual rate of Δ of weight (kg)	+	−0.34 ± 4.54	1.52 ± 8.69	0.105
Annual rate of Δ of BMI (kg/m2)	+	−0.06 ± 1.60	0.75 ± 3.01	0.042
Exploratory Outcome Measures
% with annual rate of Δ of TMS ≤ −3.3	+	20.8%	23.4%	.698*^

Results of Sub‐Analysis
	Direction of favorable Δ	TBZ Group	Olanzapine Group	p‐value
N		18	27
Primary Outcome Measure
Annual rate of Δ of TMS	−	3.58 ± 8.28	0.55 ± 9.28	0.270
Secondary Outcome Measures
Absolute Δ of TMS	−	3.56 ± 9.60	0.82 ± 8.59	0.323
Percent Δ of TMS	−	16.89 ± 30.38	2.35 ± 21.78	0.068
Annualized percent Δ of TMS	−	17.58 ± 29.96	1.23 ± 25.57	0.057
Annual rate of Δ of total chorea score	−	−0.76 ± 0.3.98	−1.46 ± 5.82	0.658
Annual rate of Δ of TFC	+	−0.33 ± 1.82	−1.03 ± 1.74	0.201
Annual rate of Δ of weight (kg)	+	0.72 ± 4.54	5.15 ± 6.86	0.022
Annual rate of Δ of BMI (kg/m2)	+	0.30 ± 1.63	1.87 ± 2.52	0.027
Exploratory Outcome Measures
% with annual rate of Δ of TMS ≤ −3.3	+	11.1%	29.6%	.158*^

Abbreviations: BMI: Baseline body mass index; TBZ: tetrabenazine; TFC: Total Functional Capacity score; TMS: total motor score.

All results that are not percentages represent mean ± standard deviation.